Thursday, April 23, 2020 3:51:54 PM
Thanks for getting back to me. I recommend that SCYX issue a good-will corporate update ASAP, to calm your plunging PPS.
I also recommend that for future Warrants, to the extent there are remaining issued Warrants, they be reduced 1-for-1 when the related Common Shares are sold.
Your press release on Apr 21 reported very exciting news. This typically would attract new buyers & rewards existing Shareholders. However, the PPS has dropped around -28% since Apr 21. WHY is this?
Going forward, SCYX really needs to craft a better 1-for-1 warrants policy. The long term investors are getting severely punished by your last “selective” Public Offering Warrants.
There appears to be a strategic round trip strategy in-play at the $1.05+ to $1.10+ PPS levels. The Offering purchasers sell massive amounts of the Offering $.90 Common Shares because the 1.10 Warrants can, in the future, replenish shares sold. Also, If desirable, these same purchasers buy/increase the Common Shares when the PPS subsequently seems to bottom.
The aforementioned Warrant Holders are making huge profits by selling Common Shares (per above) while maintaining all of their Warrants. This massive selling precipitates anger & or panic selling to further plunge the PPS. To add insult to injury, at the bottoming of the PPS, Common Shares can be bought back by the selective Public Offering purchasers.
It should be noted that your future funding needs are compromised by lower (than justifiable) PPS because of the above matters.
Please forward this email to your Management.
Recent SCYX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/16/2024 12:00:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/10/2024 12:01:19 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 08:01:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/20/2024 12:07:47 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 06/20/2024 12:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 08:01:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 10:48:23 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 02:09:53 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:41:39 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 09:32:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/30/2024 09:03:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/30/2024 09:01:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/30/2024 09:01:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 02:53:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2024 09:01:09 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/28/2023 09:05:54 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/28/2023 09:05:51 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/28/2023 05:15:14 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 11/13/2023 10:09:33 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 11/13/2023 09:45:07 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:01:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/02/2023 01:15:16 PM
- SCYNEXIS Issues a Voluntary Nationwide Recall of BREXAFEMME® (ibrexafungerp tablets) due to potential for cross contamination with a non-antibacterial ß-lactam drug substance • GlobeNewswire Inc. • 09/28/2023 12:31:05 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/25/2023 12:32:25 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM